Critical shortage in BCG immunotherapy: How did we get here and where will it take us?

Intravesical Bacillus Calmette-Guérin vaccine, one of the most successful bio-therapies to date, has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years. International shortages have necessitated rationing this life-saving medication with deleterious effects on the primary treatment of high-grade non-muscle invasive bladder cancer. Understanding the history of intravesical Bacillus Calmette-Guérin gives us insight into the current shortages and future perspectives for novel immunotherapy opportunities against this deadly disease.

Urologic oncology. 2021 Nov 05 [Epub ahead of print]

Michael Harvey, Bodie Chislett, Marlon Perera, Nathan Lawrentschuk, Damien Bolton, Gregory Jack

Department of Urology, Olivia Newton-John Cancer Centre at Austin Health, University of Melbourne, Melbourne, Australia; Department of Urology, Western Health, Melbourne, Australia. Electronic address: ., Department of Urology, Olivia Newton-John Cancer Centre at Austin Health, University of Melbourne, Melbourne, Australia., Department of Urology, Olivia Newton-John Cancer Centre at Austin Health, University of Melbourne, Melbourne, Australia; Department of Urology, Western Health, Melbourne, Australia., Uro-Oncology Service, Peter MacCallum Cancer Centre, Victoria Comprehensive Cancer Centre, Melbourne, Australia.

email news signup